Ajax Engineering IPO opened for subscription on February 10, 2025 and closed on February 12, 2025.

It was a book-built issue of ₹1,269.35 crore. The issue was totally an offer for sale of 2.02 crore shares. The Ajax Engineering IPO price band was set at ₹629 per share.

On Day 3 of subscription, February 12, as of 5:04 PM, Ajax Engineering IPO was subscribed 6.06 times. QIBs subscribed 13.04x, NIIs subscribed 6.46x, and retail investors subscribed 1.94x.

The share allotment was finalised on Thursday, February 13, 2025, and the shares were listed on BSE and NSE on February 17, 2025.

Ajax Engineering Share Price

On the listing day, on the NSE, Ajax Engineering share price opened at ₹576.00, down from its issue price of ₹629.00. At 10:37 AM, the share price was trading at ₹584.80, up by 1.53% from its opening price of ₹576.00. As of the same time, the stock touched its day’s high at ₹594.00. The company’s market cap was ₹6,691.08 crore.

On the BSE, at 10:41 AM, Ajax Engineering share price was trading at ₹581.40, up by 1.96% from its opening price of ₹593.00 and 7.57% up from its issue price of ₹629.00.

About Ajax Engineering Limited

Ajax Engineering is a manufacturer of concrete equipment, offering a comprehensive range of equipment, services, and solutions across the concrete application value chain. As of September 30, 2024, the company has developed over 141 concrete equipment variants catering to various applications in the concrete value chain. Over the past decade, it has sold more than 29,800 units of concrete equipment in India. With 32 years of experience, the company boasts a wide product portfolio, including self-loading concrete mixers (SLCMs), batching plants for concrete production, transit mixers for transportation, boom pumps, concrete pumps, self-propelled boom pumps, slip-form pavers, and 3D concrete printers for concrete deposition.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Zen Technologies Limited has been in focus on Monday, after the company announced its financial results for Q3 and 9M FY 2025.

On February 17, 2025, Zen Technologies share price opened at ₹1,206.00, down from its previous close of ₹1,350.00. At 11:07 AM, the share price of Zen Technologies was trading at ₹1,080.00, down by 20.00% on the NSE.

Q3 and 9M FY 2025 Financial Highlights

For Q3 FY25, the company reported a standalone revenue of ₹141.52 crore, marking a 44% year-on-year (YoY) growth. Its profit after tax (PAT) stood at ₹38.62 crore, reflecting a 22% YoY increase. The company’s EBITDA for the quarter was ₹58.69 crore, showing a 21% YoY rise.

For the nine months ending FY25, the company reported a standalone revenue of ₹637.17 crore, reflecting a 116% year-on-year growth. Its PAT stood at ₹178.03 crore, marking an 85% YoY increase. The company’s EBITDA for the period was ₹252.77 crore, showing a 76% YoY rise.

Management Commentary

Commenting on the performance for the quarter, the Chairman and Managing Director, Mr Ashok Atluri, said, “I am pleased to provide an update on our Q3FY25 performance, which demonstrates a stable performance, keeping us on track to meet our stated guidance of ₹900 crores revenues for FY25. The Union Budget 2025 demonstrates the government’s commitment to strengthening the defence sector, with a record allocation of over ₹6.81 lakh crore for the Ministry of Defence, marking a 9.53% increase from FY25. This includes a substantial ₹1.80 lakh crore earmarked under the Capital Budget of Armed Forces, providing significant tailwinds for our industry.”

He further stated that their liquidity remains strong, with ₹1,028 crores in bank balances as of December 31, 2024. Furthermore, the company completed the expansion of their assembly unit at Maheshwaram. This expansion improves their ability to scale up operations to meet growing demand.

According to the Chairman and Managing Director, the company’s order book remains strong at ₹816.91 crore as of December 2024, indicating a healthy pipeline for the upcoming quarters. Their strategic focus on securing new contracts and diversifying their portfolio ensures sustained revenue visibility and positions them for continued growth.

The company has also made strategic acquisitions in robotics, aerospace, and defence propulsion to further solidify its leadership in cutting-edge technology. These acquisitions include Vector Technics, a leader in electrical propulsion and IC engine technology for UAVs and robotics, and Bhairav Robotics, which specialises in combat robotics and autonomous systems for defence and industrial applications, said Ashok Atluri.

Additionally, the acquisition of Applied Research International (ARI) and ARI Labs strengthens their defence simulation capabilities, extending their technological reach into naval and maritime domains.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Glenmark Pharmaceuticals Limited announced its financial results for the third quarter ended December 31 2024.

On February 17, 2025, Glenmark share price opened at ₹1,320.00, down from its previous close of ₹1,323.05. At 9:55 AM, the share price of Glenmark was trading at ₹1,333.00, up by 0.75% on the NSE.

Q3 FY 2025 Financial Highlights

Glenmark Pharmaceuticals reported that consolidated revenue rose 35.1% YoY to ₹33,876 million from ₹25,067 million in Q3 FY24. The company’s EBITDA stood at ₹6,002 million, reflecting an EBITDA margin of 17.7%.

Profit After Tax (PAT) for the quarter was ₹3,480 million, with a PAT margin of 10.3%.

The company stated that in India, sales from the formulation business surged 300.2% YoY to ₹10,637 million from ₹2,658 million in the previous year. North America saw a modest 1.4% YoY growth in finished dosage formulations, reaching ₹7,813 million.

Revenue from the RoW (Asia, MEA, LATAM, and RCIS) segment grew 3% YoY to ₹7,491 million, though adverse currency movements in key markets impacted overall performance. Meanwhile, Glenmark’s Europe operations recorded a 14.8% YoY increase, with revenue rising to ₹7,297 million from ₹6,357 million in Q3 FY24.

Management Commentary

Commenting on the performance, the Chairman and Managing Director of Glenmark Pharmaceuticals Ltd, Glenn Saldanha, said, “We delivered strong and sustained growth this quarter, driven by robust performance across the regions. Our European business continued to perform well, while our branded markets demonstrated resilient growth. Strengthening our value-chain strategy, we secured MHRA authorization for WINLEVI® in the UK, marking a pivotal step in expanding our dermatology portfolio.”

He further added, “Looking ahead, we expect our North American business to gain momentum from FY26 onwards, supported by our growing respiratory and injectable portfolio. Additionally, we reached a significant milestone with IGI presenting promising first clinical data from our Phase 1 study of the trispecific TREAT™ antibody, ISB 2001, at the 66th American Society of Hematology (ASH) Annual Meeting. We continue to explore strategic partnerships to advance this asset.”

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd is a global, research-driven pharmaceutical company with a strong presence in the branded, generic, and OTC segments. It specialises in key therapeutic areas such as respiratory, dermatology, and oncology. With operations spanning over 80 countries, Glenmark operates 11 state-of-the-art manufacturing facilities across four continents.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Bharat Forge Limited’s Board of Directors has declared and approved an interim dividend of ₹2.50 per equity share of the face value of ₹2 each.

On February 14, 2025, Bharat Forge share price (NSE: BHARATFORG) opened at ₹1,088.75 and closed at ₹1,077.65, up by 0.13%. The stock price touched its day’s high at ₹1,106.30.

Bharat Forge Dividend Record Date

The company has declared an interim dividend of ₹2.50 per equity share (125% of the face value of ₹2 each). The company stated that the dividend will be paid on or before March 12, 2025, to shareholders whose names appear in the Register of Members or as beneficial owners in depository records as of the record date, February 18, 2025.

Q3 FY 2025 Financial Highlights

In Q3 FY25, the company reported consolidated total revenue of ₹34,756 million, with Indian operations contributing ₹23,771 million, overseas operations ₹10,979 million, and e-mobility ₹6 million. The consolidated EBITDA stood at ₹6,378 million, with Indian operations at ₹6,459 million, overseas operations at ₹38 million, and e-mobility at a loss of ₹120 million. The company’s consolidated PBT was ₹3,522 million, with Indian operations at ₹5,030 million, while overseas operations and e-mobility recorded losses of ₹1,344 million and ₹164 million, respectively.

About Bharat Forge Limited

Bharat Forge is involved in the manufacturing and selling of forged and machined compoundant for the auto and industry sectors.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Oil India Limited’s Board of Directors has declared and approved an interim dividend of ₹7 per equity share.

On February 14, 2025, Oil India share price (NSE: OIL) opened at ₹415.00 and closed at ₹395.65, down by 4.18%. The stock price touched its day’s low at ₹390.10.

Oil India Dividend Record Date

The company’s board of directors have declared a second interim dividend of ₹7 per share (70% of paid-up capital) for the financial year 2024-25. The company stated that the dividend will be paid on or before March 9, 2025. The record date for determining shareholder eligibility for this dividend is set as Monday, February 17, 2025.

Q3 FY 2025 Financial Highlights

Oil India reported 9M FY25 results, where, for the nine months ending December 31, 2024, crude oil production rose by 4.10% to 2.614 MMT from 2.511 MMT in the corresponding period of FY24, while cumulative gas production increased by 2.90% to 2,446 MMSCM from 2,377 MMSCM.

Higher crude production contributed to a 28.38% rise in PAT, reaching ₹4,522.71 crore from ₹3,523.02 crore in the previous year. EBITDA margin improved to 42.76% from 41.34% in Q3 FY24. Additionally, the company’s group PAT for the nine-month period grew by 19.26% to ₹5,542.66 crore from ₹4,647.51 crore in the corresponding period of FY24.

About Oil India Ltd

Oil India Ltd is involved in exploration, development and production of crude oil and natural gas, transportation of crude oil and production of LPG. It also offers various E&P-related services for oil blocks.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Laxmi Dental Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2024.

On February 14, 2025, Laxmi Dental share price opened at ₹426.00, up from its previous close of ₹419.90. At 10:15 AM, the share price of Laxmi Dental was trading at ₹410.70, down by 2.19% on the NSE. Notably, the stock price touched its 52-week low at ₹408.60, today.

Laxmi Dental Q3 & 9M FY 2025 Financial Highlights

For the third quarter of FY25, the company reported revenues of ₹616.6 million, marking a 29.0% year-on-year (YoY) growth compared to ₹477.9 million in Q3 FY24. For the nine months ended December 31, 2024, revenues stood at ₹1,784.4 million, reflecting a 28.8% increase from ₹1,385.1 million in the corresponding period of the previous year.

The company’s gross profit for Q3 FY25 was ₹455.7 million, up 32.1% YoY from ₹345.0 million in Q3 FY24. The gross profit margin improved to 73.9% in Q3 FY25 from 72.2% in the previous year. For the nine-month period, gross profit reached ₹1,340.9 million, up 31.0% from ₹1,023.5 million, with a gross profit margin of 75.1%.

EBITDA for Q3 FY25 surged 144.7% YoY to ₹96.1 million, compared to ₹39.3 million in Q3 FY24, with an improved EBITDA margin of 15.6% versus 8.2% in the previous year. For the nine-month period, EBITDA stood at ₹389.7 million, up 167.2% from ₹121.1 million, with a margin expansion to 18.1% from 8.7% in 9M FY24.

The company’s profit after tax (PAT), after accounting for the share of profit/loss from joint ventures, doubled in Q3 FY25 to ₹48.2 million, reflecting a 105.0% YoY increase from ₹23.5 million in Q3 FY24. For the nine months ended December 31, 2024, PAT stood at ₹275.6 million, up 57.3% from ₹175.3 million in the prior year.

Management Commentary 

Commenting on the results, the management stated, “We are pleased to see such an amazing response to our IPO. We thank all the shareholders for reposing their faith in us. We welcome our new shareholders & congratulate all stakeholders for the successful listing. Today, Laxmi Dental has established a leadership position in this space with a comprehensive portfolio of products catering to overall dental care requirements. This enables us to capture a large pie of this sizable and growing market by deepening our existing dental network as well as adding new customers in various geographies. Over the next 3-5 years we expect to continue on this trajectory and grow at a CAGR of 20 to 25%.”

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.